Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi Therapeutics (MGX) Other Accumulated Expenses (2024 - 2025)

Metagenomi (MGX) has disclosed Other Accumulated Expenses for 2 consecutive years, with $165000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 63.0% to $165000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $165000.0 through Dec 2025, down 63.0% year-over-year, with the annual reading at $165000.0 for FY2025, 63.0% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $165000.0 at Metagenomi, down from $312000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $446000.0 in Q4 2024, with the low at $117000.0 in Q1 2025.